Acadia presents additional data on Alzheimer’s psychosis drug
Acadia Pharmaceuticals (NASDAQ:ACAD) presented additional data from its Phase 2 RADIANT trial of remlifanserin for Alzheimer’s disease psychosis, showing consistent efficacy signals at the 60 mg dose. The drug previously missed its primary endpoint but achieved nominal significance on key secondary endpoints. The company continues Phase 3 trials and is also investigating the drug for Lewy body dementia psychosis.
How this was made
The 30-second read
Why it matters
The update highlights additional efficacy signals for the 60 mg dose on CGI-I-ADP and NPI/NPI-NH psychosis measures, alongside safety/tolerability similar to placebo, which can shift sentiment toward the Phase 3 program.
Market read
Conference-published secondary and exploratory efficacy improvements for the 60 mg dose can drive short-term re-rating of the clinical program, but the earlier primary endpoint miss remains a key overhang.
What to watch
Traders may discount nominal p-values and subgroup threshold effects if multiplicity and prespecification are unclear, and will likely wait for Phase 3 readouts rather than conference add-ons.
Background
Acadia’s remlifanserin is being studied in Phase 2 RADIANT for Alzheimer’s disease psychosis, with Phase 3 advancement underway.
Ticker impact
Acadia presented new Phase 2 RADIANT analyses for remlifanserin, including CGI-I-ADP separation at Weeks 2, 4, and 6 and Week 6 responder rates vs placebo.
Likely modest upward bias as traders re-rate the program on added efficacy signals, while remaining cautious due to the earlier primary endpoint narrowly missing.
The article adds specific nominal p-values and responder-rate comparisons for the 60 mg dose, plus safety being similar to placebo, but it does not report a new primary endpoint win or regulatory decision.
Market effects
Reinforces investor focus on Alzheimer’s disease psychosis trial read-throughs and the value of secondary endpoint and subgroup threshold analyses in biotech risk models.
Limited, primarily affects US-listed biotech sentiment rather than broader regional risk.
Low, as the catalyst is company-specific clinical-trial data presented at a conference.
Counterpoint
Because the primary endpoint was still narrowly missed, the new analyses may be viewed as post-hoc or exploratory, limiting how much the market should re-rate Phase 3 success probability.
Key entities
- companyAcadia Pharmaceuticals Inc.
NASDAQ-listed developer of remlifanserin for Alzheimer’s disease psychosis; presented additional Phase 2 RADIANT analyses.
- drugremlifanserin
Acadia’s investigational therapy evaluated in Phase 2 RADIANT and also in a Phase 2 study for Lewy body dementia psychosis.
- clinical_programRADIANT trial
Phase 2 program in Alzheimer’s disease psychosis; new analyses presented at the Clinical Trials on Alzheimer’s Disease conference.


